Treatment of experimental murine pancreatic peritoneal carcinomatosis with fibroblasts genetically modified to express IL12: A role for peritoneal innate immunity

Gut

Volumn 56, Issue 1, 2007, Pages 107-114

  Peron J M ^a,b   Bureau, C ^b   Gourdy, P ^b   Lulka, H ^b   Souque, A ^b   Calippe, B ^b   Selves, J ^b   Al Saati, T ^b   Bernad, J ^c   Cordelier, P ^b   Couderc, B ^b   Pradayrol, L ^b   Pipy, B ^a,c   Buscail, L ^b   Vinel, J P ^b  

^a CHU PURPAN   (France)

^b INSERM   (France)

^c UPRES EA 820 Fac Sci P   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12; NITRIC OXIDE; PROTEIN P35; PROTEIN P40; PROTEIN SUBUNIT; REACTIVE OXYGEN METABOLITE; RETROVIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CARCINOMATOUS PERITONITIS; CELL ACTIVATION; CELL INFILTRATION; CONTROLLED STUDY; DNA MODIFICATION; EX VIVO GENE TRANSFER; EXPERIMENTAL STUDY; FEMALE; FIBROBLAST; FLOW CYTOMETRY; GENETIC CODE; HUMAN; HUMAN CELL; IN VITRO STUDY; INNATE IMMUNITY; INOCULATION; MACROPHAGE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PANCREAS CARCINOMA; PERITONEUM LAVAGE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; FIBROBLASTS; FLOW CYTOMETRY; GENE THERAPY; IMMUNITY, NATURAL; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAPERITONEAL; INTERLEUKIN-12; MACROPHAGES; MICE; MICE, INBRED BALB C; MICE, NUDE; NITRIC OXIDE; PANCREATIC NEOPLASMS; PERITONEAL NEOPLASMS; REACTIVE OXYGEN SPECIES;

EID: 33846001023     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2005.083477     Document Type: Article

References (20)

1. Chu DZ, Lang NP, Thompson C, et al. Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer 1989;63:364-7.
2. Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from nongynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 2000;88:358-63.
3. Glehen O, Mohamed F, Gilly FN. Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet Oncol 2004;5:219-28.
4. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 1995;13:251-76.
5. Shurin MR, Esche C, Péron JM, et al. Antitumor activities of IL-12 and mechanisms of action. Chem Immunol 1997;68:153-74.
6. Kobayashi M, Fitz L, Ryan M, et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 1989;170:827-45.
7. Stern AS, et al. Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. Proc Natl Acad Sci USA 1990;87:6808-12.
8. Gately MK, Desai BB, Wolitzky AG, et al. Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J Immunol 1991;147:874-82.
9. Sgadari C, Angiolillo AL, Tosato G. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood 1996;87:3877-82.
10. Yao L, Sgadari C, Furuke K, et al. Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. Blood 1999;93:1612-21.
11. Masztalerz A, Van Rooijen N, Den Otter W, et al. Mechanisms of macrophage cytotoxicity in IL-2 and IL-12 mediated tumour regression. Cancer Immunol Immunother 2003;52:235-42.
12. Gollob JA, Mier JW, Atkins MB. Clinical use of systemic IL-12 therapy. In: Giaccone G, Schilsky R, Sondel P, eds. Cancer chemotherapy and biological response modifiers. Annual 19. Amsterdam: Elsevier Science BV, 2001:353-69.
13. Péron JM, Couderc B, Rochaix P, et al. Treatment of murine hepatocellular carcinoma using genetically modified cells to express interleukin-12. J Gastroenterol Hepatol 2004;19:388-96.
14. Tahara H, Zitvogel L, Storkus WJ, et al. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J Immunol 1995;154:6466-74.
15. Coste A, Dubourdeau M, Linas MD, et al. PPARgamma promotes mannose receptor gene expression in murine macrophages and contributes to the induction of this receptor by IL-13. Immunity 2003;19:329-39.
16. Péron JM, Shurin M, Lotze MT. Cytokine gene therapy of cancer. In: Lattime EC, ed. Gene therapy of cancer. San Diego: Academic Press, 1999:359-71.
17. Elder EM, Lotze, MT, Whiteside TL. Successful culture and selection of cytokine gene-modified human dermal fibroblasts for the biologic therapy of patients with cancer. Hum Gene Ther 1996;7:479-87.
18. Chizzonite R, Truitt T, Desai BB, et al. IL-12 receptor. I. Characterization of the receptor on phytohemagglutinin-activated human lymphoblasts. J Immunol 1992;148:3117-24.
19. Mantovani A, Sozzani S, Locati M, et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002;23:549-55.
20. Cox GW, Melillo G, Chattopadhyay U, et al. Tumor necrosis factor-alpha-dependent production of reactive nitrogen intermediates mediates IFN-gamma plus IL-2-induced murine macrophage tumoricidal activity. J Immunol 1992;149:3290-6.